Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Xizang Weixinkang Pharmaceutical Co EBITDA Margin % Related Terms
Xizang Weixinkang Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xizang Weixinkang Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a EBITDA Margin % of 24.96% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. This is 39% above median its historical median of 18.00. Over the past decade, Xizang Weixinkang Pharmaceutical Co's EBITDA Margin % has ranged from 9.66 to 30.49. According to the industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #234 out of 960 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Xizang Weixinkang Pharmaceutical Co's EBITDA Margin % too high?
Xizang Weixinkang Pharmaceutical Co's current EBITDA Margin % of 24.96% is 39% above median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 9.66 to a high of 30.49. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Xizang Weixinkang Pharmaceutical Co's value of 24.96% is 99.4% above this industry median. Based on the distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #234 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #234 out of 960 companies for EBITDA Margin %. This places Xizang Weixinkang Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Xizang Weixinkang Pharmaceutical Co's value of 24.96% is 99.4% above this benchmark. Historically, Xizang Weixinkang Pharmaceutical Co's own EBITDA Margin % has ranged from 9.66 to 30.49 over the past decade. While the company's 10-year median is 18.00 vs. the industry median of 12.52, Xizang Weixinkang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xizang Weixinkang Pharmaceutical Co's current EBITDA Margin % of 24.96% is 99.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xizang Weixinkang Pharmaceutical Co's current EBITDA Margin % is 24.96%, which is 39% above median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.93, compared to a current price of ¥8.78 — trading 1.7% below its estimated fair value. The current EBITDA Margin % is 24.96%, which is 39% above median its 10-year median of 18.00 and 99.4% above the Drug Manufacturers industry median of 12.52. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current EBITDA Margin % is 24.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.78 is trading 1.7% below its estimated GF Value™ of ¥8.93.
GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603676:
EBITDA Margin %: 24.96% (39% above median its 10-year median of 18.00)
GF Value™: ¥8.93 vs. price of ¥8.78 (1.7% below fair value)
Industry Position: 99.4% above the Drug Manufacturers median (#234 of 960)
No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xizang Weixinkang Pharmaceutical Co Business Description
AddressYuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
74GF Score
Get the complete analysis for SHSE:603676
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603676 has been successfully added to your 
